# Entrada Therapeutics, Inc.: overview

TRDA · Nasdaq · CIK 1689375 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trda.md) · [Financials](/companies/trda/financials.md) · [Filings](/companies/trda/filings.md) · [Insiders](/companies/trda/insiders.md)

Latest reported revenue: [$898.0k](/filings/0001689375-26-000054.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001689375-26-000054).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.6](/filings/0001689375-25-000050.md) | [37.4 d](/filings/0001689375-26-000011.md) | [20.6](/filings/0001689375-26-000028.md) | [2.0](/filings/0001689375-26-000054.md) | [1.6](/filings/0001689375-25-000050.md) | [1.3 d](/filings/0001689375-26-000011.md) | [0.9](/filings/0001689375-26-000028.md) | [0.9](/filings/0001689375-26-000054.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(110.7%)](/filings/0001689375-25-000050.md) | [(15.7%) d](/filings/0001689375-26-000011.md) | [(106.0%)](/filings/0001689375-26-000028.md) | [(2402.5%)](/filings/0001689375-26-000054.md) | [(2915.2%)](/filings/0001689375-25-000050.md) | [(3249.3%) d](/filings/0001689375-26-000011.md) | [(4834.6%)](/filings/0001689375-26-000028.md) | [(5007.0%)](/filings/0001689375-26-000054.md) |
| Net margin | % | [(71.7%)](/filings/0001689375-25-000050.md) | [3.0% d](/filings/0001689375-26-000011.md) | [(84.4%)](/filings/0001689375-26-000054.md) | [(2210.4%)](/filings/0001689375-26-000054.md) | [(2734.4%)](/filings/0001689375-25-000050.md) | [(3014.9%) d](/filings/0001689375-26-000011.md) | [(4539.1%)](/filings/0001689375-26-000054.md) | [(4762.0%)](/filings/0001689375-26-000054.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001689375-25-000050.md) | not reported | [(0.42)](/filings/0001689375-26-000028.md) | [(1.04)](/filings/0001689375-26-000054.md) | [(1.06)](/filings/0001689375-25-000050.md) | not reported | [(0.95)](/filings/0001689375-26-000028.md) | [(1.01)](/filings/0001689375-26-000054.md) |
| Free cash flow | $m | [(24.9) d](/filings/0001689375-25-000050.md) | [(32.2) d](/filings/0001689375-26-000011.md) | [(39.7)](/filings/0001689375-26-000028.md) | [(29.8) d](/filings/0001689375-26-000054.md) | [(28.5) d](/filings/0001689375-25-000050.md) | [(32.4) d](/filings/0001689375-26-000011.md) | [(41.7)](/filings/0001689375-26-000028.md) | [(32.5) d](/filings/0001689375-26-000054.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [129](/filings/0001689375-25-000011.md) | [211](/filings/0001689375-26-000011.md) | [25.4](/filings/0001689375-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(2.5%)](/filings/0001689375-25-000011.md) | [22.3%](/filings/0001689375-26-000011.md) | [(621.1%)](/filings/0001689375-26-000011.md) |
| Net margin | % | not reported | not reported | [(5.2%)](/filings/0001689375-25-000011.md) | [31.1%](/filings/0001689375-26-000011.md) | [(565.5%)](/filings/0001689375-26-000011.md) |
| Diluted EPS | $ per share | [(8.16)](/filings/0001689375-23-000019.md) | [(3.02)](/filings/0001689375-24-000016.md) | [(0.20)](/filings/0001689375-25-000011.md) | [1.68](/filings/0001689375-26-000011.md) | [(3.47)](/filings/0001689375-26-000011.md) |
| Free cash flow | $m | [(55.4)](/filings/0001689375-23-000019.md) | [(96.7)](/filings/0001689375-24-000016.md) | [134](/filings/0001689375-25-000011.md) | [(44.7)](/filings/0001689375-26-000011.md) | [(130)](/filings/0001689375-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/trda/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $37.3m | 5,072,730 |  | Unchanged |
| [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $29.9m | 4,056,379 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $19.0m | 2,583,333 |  | Added +224,540 |
| [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $12.8m | 1,739,768 |  | New +1,739,768 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.3m | 1,269,634 |  | Added +13,621 |
| [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $9.2m | 1,253,053 |  | New +1,253,053 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $7.8m | 1,060,230 |  | Reduced −1,227,270 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $7.0m | 954,419 |  | Reduced −80,363 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $5.6m | 763,959 |  | Added +244,603 |
| [StepStone Group LP](/funds/1502287.md) | 2026-06-30 | $5.6m | 761,277 |  | Unchanged |

## Recent filings

[All 471 filings](/companies/trda/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 11:52 ET | [8-K](/filings/0001689375-26-000057.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001689375-26-000057 |
| 2026-09-10 | 20:26 ET | [SCHEDULE 13D/A](/filings/0001231919-26-001160.md) | Ownership report, active investor, amended | 0001231919-26-001160 |
| 2026-08-05 | 11:11 ET | [10-Q](/filings/0001689375-26-000054.md) | Quarterly report, period 2026-06-30 | 0001689375-26-000054 |
| 2026-08-05 | 11:04 ET | [8-K](/filings/0001689375-26-000052.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001689375-26-000052 |
| 2026-06-10 | 20:06 ET | [8-K](/filings/0001104659-26-072326.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-072326 |
| 2026-05-19 | 22:32 ET | [8-K](/filings/0001104659-26-063325.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-063325 |
| 2026-05-07 | 11:14 ET | [10-Q](/filings/0001689375-26-000028.md) | Quarterly report, period 2026-03-31 | 0001689375-26-000028 |
| 2026-05-07 | 11:11 ET | [8-K](/filings/0001689375-26-000027.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001689375-26-000027 |
| 2026-04-24 | 12:30 ET | [DEF 14A](/filings/0001689375-26-000021.md) | Proxy statement, period 2026-06-10 | 0001689375-26-000021 |
| 2026-02-26 | 12:09 ET | [10-K](/filings/0001689375-26-000011.md) | Annual report, period 2025-12-31 | 0001689375-26-000011 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001689375-26-000011.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/be70b8dd-4a2b-4543-be8e-1540343297ef)

## About the filer

- CIK: 1689375
- Tickers: TRDA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.